Market didn’t seem to like the large loss due to IPO costs and EBITDA breakeven by 2026 vs expected 2025 but revenue guidance beat and they’re upholding their very aggressive gross margin guidance. A look at my tracker shows it’s trading at the same trailing sales multiple as PACB but still trading at higher forward multiples, which is interesting as PACB has higher growth. Investors must be very confident and skeptical of ONT and PACB hitting targets respectively.
3 Likes